Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
INNOVAR vs COLYTE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Innovar is a combination of fentanyl (mu-opioid receptor agonist) and droperidol (butyrophenone antipsychotic that blocks dopamine D2 receptors in the CNS, producing sedation and antiemetic effects).
Colyte is a polyethylene glycol (PEG)-based osmotic laxative that induces diarrhea by retaining water in the gastrointestinal tract via osmotic forces, thereby cleansing the colon.
Neuroleptanalgesia for surgical and diagnostic procedures,Adjunct to general anesthesia
Bowel preparation prior to colonoscopy,Bowel preparation prior to barium enema,Bowel preparation prior to colorectal surgery
2-5 m L (droperidol 2.5-5 mg and fentanyl 0.05-0.1 mg) IM/IV every 1-2 hours as needed for neuroleptanalgesia; surgical anesthesia: initial 1 m L/10 kg IM or slow IV, then 0.5 m L increments.
4 L oral solution administered as a single dose at a rate of 240 m L every 10 minutes until complete.
Droperidol: terminal t1/2 2.2–2.5 h (infants 4.5 h). Fentanyl: terminal t1/2 3–7 h (mean ~4 h) in adults; prolonged in elderly (up to 16 h) and hepatic impairment.
Not applicable; systemic absorption is negligible (<0.06%), so a terminal elimination half-life is clinically irrelevant. The gastrointestinal transit time for the solution is approximately 1-3 hours.
Fentanyl: CYP3A4 to norfentanyl; Droperidol: CYP3A4 and CYP1A2 to multiple metabolites.
Polyethylene glycol is not significantly metabolized and is excreted largely unchanged in feces.
Droperidol: ~75% renal as metabolites, ~22% biliary/fecal. Fentanyl: primarily renal as metabolites (85%), ~9% fecal.
COLYTE (polyethylene glycol 3350 and electrolytes) is minimally absorbed; <0.1% of the dose is excreted renally. The majority is eliminated unchanged in feces via the gastrointestinal tract, with fecal excretion accounting for >99%.
Fentanyl: ~80–85% bound to albumin and α1-acid glycoprotein. Droperidol: ~85–90% bound to albumin and α1-acid glycoprotein.
Not applicable; negligible systemic absorption, so protein binding is clinically irrelevant.
Fentanyl: Vd 3–5 L/kg (large distribution to tissues, slow elimination). Droperidol: Vd 1.5–2 L/kg (moderate distribution).
Not applicable; negligible systemic absorption, so volume of distribution is clinically irrelevant.
Fentanyl: IV 100%; transdermal 92% (after depot formation); transmucosal ~50% (buccal) to 70% (nasal); oral <30% due to first-pass. Droperidol: IV 100%; IM ~85% (well absorbed).
Oral: <0.1% (systemic bioavailability is negligible due to minimal absorption of polyethylene glycol).
e GFR >60 m L/min: no adjustment; e GFR 30-60: reduce dose by 25-50% due to fentanyl accumulation; e GFR <30: avoid or use with extreme caution, reduce dose by ≥50%, monitor for respiratory depression.
No dose adjustment required for renal impairment; use with caution in severe renal insufficiency (Cr Cl <30 m L/min) due to potential electrolyte imbalance.
Child-Pugh A: reduce dose by 25%; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated due to impaired fentanyl metabolism and increased sedation risk.
No specific dose adjustments for hepatic impairment; use with caution in severe hepatic disease.
Not FDA-approved for pediatric use; limited data: 0.1 m L/kg (droperidol 0.125 mg/kg + fentanyl 0.0025 mg/kg) IM/IV as single dose; max 1.5 m L. Contraindicated in neonates.
Pediatric patients (≥6 months): 25-40 m L/kg/hour orally or via nasogastric tube until rectal effluent is clear; maximum 4 L.
Reduce initial dose by 50-75% (e.g., 0.5-1 m L IM/IV); titrate cautiously; increased risk of hypotension, respiratory depression, and prolonged sedation; monitor renal function.
No specific dose adjustment; monitor for dehydration and electrolyte disturbances due to reduced renal reserve.
Risk of respiratory depression, especially in elderly, debilitated, or opioid-naive patients; risk of QT prolongation and torsade de pointes with droperidol, including at recommended doses.
None
Monitor respiratory function; avoid in patients with bradycardia, electrolyte abnormalities, or QT prolongation; risk of hypotension, neuroleptic malignant syndrome, and extrapyramidal symptoms.
Risk of electrolyte disturbances (especially in patients with renal impairment or those taking medications affecting electrolytes), aspiration risk (use with caution in patients with impaired gag reflex or at risk of regurgitation), serious fluid and electrolyte abnormalities, cardiac arrhythmias, seizures, and serious adverse reactions including ischemic colitis and ulcerative colitis. Use with caution in patients with severe ulcerative colitis, toxic megacolon, or gastrointestinal obstruction.
Hypersensitivity to fentanyl, droperidol, or components; known QT prolongation; concurrent MAOIs; severe respiratory depression; myasthenia gravis.
Gastrointestinal obstruction, bowel perforation, toxic megacolon, gastric retention, ileus, known hypersensitivity to any component of the product.
Avoid grapefruit juice as it may increase fentanyl levels via CYP3A4 inhibition. No specific food restrictions for droperidol. Maintain adequate hydration to prevent hypotension, but monitor for fluid overload if cardiac compromise.
Avoid all solid foods during bowel preparation; only clear liquids (e.g., water, clear broth, apple juice, black coffee, clear soda) are permitted. Dairy products, red or purple liquids (which can mimic blood), and alcohol should be avoided. Resume a normal diet only after the procedure.
First trimester: Risk of congenital malformations, including cardiac and neural tube defects, associated with droperidol exposure. Second and third trimesters: Risk of extrapyramidal symptoms, neuroleptic malignant syndrome, and neonatal withdrawal. Fentanyl component may cause fetal respiratory depression and intrauterine growth restriction. Use only if maternal benefit outweighs fetal risk.
Category C. No adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Should be used during pregnancy only if clearly needed. Potential for fetal harm due to maternal dehydration or electrolyte imbalance.
Fentanyl and droperidol are excreted in breast milk. Fentanyl M/P ratio approximately 0.2–0.4. Potential for sedation and respiratory depression in the infant. Avoid breast-feeding for 24 hours after administration. Discard milk during this period.
Not known if excreted in human milk. M/P ratio not determined. Caution advised due to potential for diarrhea in nursing infant. Use only if clearly needed.
No established dose adjustments for pregnancy. Increased clearance of fentanyl in third trimester may require higher doses for analgesic effect. Lower doses of droperidol recommended due to increased volume of distribution and prolonged effects. Use lowest effective dose and monitor for excessive sedation and hypotension.
No specific dose adjustments recommended. Pharmacokinetic changes in pregnancy not studied; standard bowel preparation dosing should be used with caution due to increased risk of fluid and electrolyte shifts.
Innovar (droperidol + fentanyl) is a neuroleptanalgesic combination; monitor for respiratory depression, hypotension, and extrapyramidal symptoms. Droperidol prolongs QTc interval; avoid in patients with electrolyte disturbances or on QT-prolonging drugs. Fentanyl is a potent mu-opioid agonist; naloxone reversal may be needed. Onset of analgesia is rapid (<2 min IV), duration 30-60 min; droperidol's sedative effect lasts 2-4 hours. Use with caution in elderly, hypovolemic, or compromised patients.
Colyte (PEG-3350 with electrolytes) is used for bowel cleansing prior to colonoscopy. Ensure adequate hydration to prevent electrolyte imbalances. Administer in divided doses; split-dose regimen improves tolerability and cleansing quality. Contraindicated in GI obstruction, gastric retention, bowel perforation, toxic colitis, or megacolon. Monitor for bloating, nausea, and vomiting; slow rate if symptoms occur.
You may feel drowsy and lightheaded; avoid driving or operating machinery for 24 hours.,Report any difficulty breathing, slow or shallow breathing, or severe dizziness immediately.,Avoid alcohol and other sedatives while taking this medication.,Inform your doctor if you have a history of heart rhythm problems, low potassium, or low magnesium.,This drug can cause involuntary muscle movements or restlessness; notify your healthcare provider if these occur.
Follow the prescribed dosing schedule exactly; do not skip doses.,Drink the entire solution as directed, typically with a split-dose regimen (half the evening before, half the morning of the procedure).,Stay well-hydrated; drink clear liquids after starting the preparation.,Avoid solid foods; only clear liquids are allowed until after the procedure.,Expect frequent, watery bowel movements; this is necessary for cleansing.,Notify your doctor if you experience severe bloating, vomiting, or signs of dehydration.,Do not take other medications within 1 hour of starting the preparation.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about INNOVAR vs COLYTE, answered by our medical review team.
INNOVAR is a Antipsychotic (Butyrophenone) that works by Innovar is a combination of fentanyl (mu-opioid receptor agonist) and droperidol (butyrophenone antipsychotic that blocks dopamine D2 receptors in the CNS, producing sedation and antiemetic effects).. COLYTE is a Osmotic Laxative that works by Colyte is a polyethylene glycol (PEG)-based osmotic laxative that induces diarrhea by retaining water in the gastrointestinal tract via osmotic forces, thereby cleansing the colon.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between INNOVAR and COLYTE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of INNOVAR is: 2-5 m L (droperidol 2.5-5 mg and fentanyl 0.05-0.1 mg) IM/IV every 1-2 hours as needed for neuroleptanalgesia; surgical anesthesia: initial 1 m L/10 kg IM or slow IV, then 0.5 m L increments.. The standard adult dose of COLYTE is: 4 L oral solution administered as a single dose at a rate of 240 m L every 10 minutes until complete.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between INNOVAR and COLYTE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. INNOVAR is classified as Category C. First trimester: Risk of congenital malformations, including cardiac and neural tube defects, associated with droperidol exposure. Second and third trimesters: Risk of extrapyramid. COLYTE is classified as Category C. Category C. No adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Should be used during pregnancy only if clearly needed. Potential for. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.